OncoMatch/Clinical Trials/NCT06788002
LDRT and Chemoimmunotherapy in NPC With Liver Metastasis
Is NCT06788002 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for nasopharyngeal cancinoma (npc).
This study aims to evaluate the efficacy and toxicity of adding low-dose radiotherapy to chemoimmunotherapy as a first-line treatment for nasopharyngeal carcinoma patients with liver metastasis.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage IVB
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: curative treatment (radical radiotherapy or radical radiotherapy combined with chemotherapy) — curative
patients who had received curative treatment (radical radiotherapy or radical radiotherapy combined with chemotherapy) and developed liver metastasis more than 6 months after treatment completion
Cannot have received: systemic anticancer therapy (including hormone therapy)
Systemic anticancer therapy, including hormone therapy, administered within 28 days prior to the initiation of the study treatment
Cannot have received: immune checkpoint inhibitor (PD-1, PD-L1, CTLA-4)
Previous treatment with immune checkpoint inhibitors (e.g., PD-1/PD-L1, CTLA-4)
Lab requirements
Blood counts
absolute neutrophil count (anc) ≥ 1.5 × 10^9/l; platelets ≥ 100 × 10^9/l; hemoglobin ≥ 90 g/l
Kidney function
serum creatinine ≤ 1.5 × uln or estimated glomerular filtration rate (egfr) ≥ 60 ml/min
Liver function
serum total bilirubin ≤ 1.5 × uln (patients with gilbert's syndrome may be included if total bilirubin < 3 × uln); ast and alt ≤ 5 × uln (because of liver metastasis)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06788002 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic anticancer therapy (including hormone therapy), immune checkpoint inhibitor disqualifies patients from enrollment.
What disease stage is eligible?
Stage IVB is required (metastatic disease required).
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages